SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Omeros Corp. operates as a biopharmaceutical company. The firm engages in the discovery, development, and commercializing of both small-molecule and protein therapeutics for large market. It also offers orphan indications targeting inflammation, coagulopathies, and disorders of the central nervous system. The company was founded by Gregory A. Demopulos and Pamela Pierce Palmer on June 16, 1994 and is headquartered in Seattle, WA.

Omeros Corporation

Omeros Corp

Omeros (OMER) is experiencing extreme volatility and intense investor focus as the market eagerly awaits an imminent FDA PDUFA decision for its life-saving drug, Narsoplimab, to treat TA-TMA. Following a trading halt for news pending, community sentiment is largely optimistic for approval, anticipating a significant price surge fueled by high short interest and the drug's first-in-class status for a condition with no existing treatment. The broader context of the recent de-risking deal with Novo Nordisk and previous regulatory hurdles fuels speculation of substantial long-term value and even a potential buyout, making this a pivotal moment for the company.

AST Spacemobile, Inc. engages in building a broadband cellular network in space to operate directly with standard, unmodified mobile devices based on an extensive IP and patent portfolio. It focuses on providing mobile broadband services with global coverage to all end-users, without the need to purchase special equipment. The company was founded by Abel Avellan on May 31, 2017 and is headquartered in Midland, TX.

AST SpaceMobile Inc - Ordinary Shares - Class A

AST SpaceMobile Inc

AST SpaceMobile is trending following the successful orbital launch of its BlueBird 6 satellite, which is touted as the largest commercial communications array ever deployed in low Earth orbit. This achievement is fueling significant bullish sentiment, with many anticipating the validation of its direct-to-device cellular broadband vision and rapid network expansion. However, discussions also reflect skepticism around the company's long-term profitability and current valuation, even as the community focuses on future scaling and execution milestones.

Intel Corp. engages in the design, manufacture, and sale of computer products and technologies. It delivers computer, networking, data storage, and communications platforms. The firm operates through the following segments: Client Computing Group (CCG), Data Center and AI (DCAI), Network and Edge (NEX), Mobileye, Accelerated Computing Systems and Graphics (AXG), Intel Foundry Services (IFS), and All Other. The CCG segment consists of platforms designed for notebooks, 2-in-1 systems, desktops, tablets, phones, wireless and wired connectivity products, and mobile communication components. The DCAI segment delivers solutions to cloud service providers and enterprise customers, along with silicon devices for communications service providers and high-performance computing customers. The NEX segment offers computing system solutions from inflexible fixed-function hardware to general-purpose compute, acceleration, and networking devices running cloud native software on programmable hardware. The Mobileye segment develops driving assistance and self-driving solutions. The AXG segment provides products and technologies designed to help customers solve the toughest computational problems. Its products include CPUs for high-performance computing and GPUs targeted for a range of workloads and platforms, from gaming and content creation on client devices to delivering media and gaming in the cloud, and the most demanding high-performance computing and AI workloads on supercomputers. The IFS segment refers to full stack solutions created from the foundry industry ecosystem. The All Other segment represents results from other non-reportable segments and corporate-related charges. The company was founded by Robert Norton Noyce and Gordon Earle Moore on July 18, 1968 and is headquartered in Santa Clara, CA.

Intel Corp.

Intel Corp

Intel is trending amid a contentious Reuters report suggesting Nvidia halted 18A chip process testing, which many in the community dismiss as 'fake news' or 'FUD' designed for market manipulation. Investors are actively discussing the true implications, with many viewing recent price dips as a buying opportunity given Intel's long-term foundry strategy and the recent FTC approval of Nvidia's $5 billion investment. The broader context of Intel's manufacturing turnaround and US government support for domestic chip production remains a key talking point.

Dynavax Technologies Corp. is a biopharmaceutical company, which engages in the provision of discovery, development, and commercialization of novel vaccines and immuno-oncology therapeutics. Its product includes HEPLISAV-B, which prevents infection caused by all known subtypes of hepatitis B virus in adults 18 years of age and older. The company was founded by Lawrence M. Lichtenstein, Dennis A. Carson, and Eyal Raz on August 29, 1996 and is headquartered in Emeryville, CA.

Dynavax Technologies Corp.

Dynavax is trending as Sanofi has announced an all-cash agreement to acquire the company, offering a significant premium for its leading hepatitis B vaccine and promising shingles pipeline. The community is actively celebrating the immediate gains for shareholders, though some express sentiment that the valuation is conservative, fueling speculation about potential competing bids. This acquisition highlights Sanofi's strategic expansion in adult vaccines and reflects the ongoing M&A activity within the biotech sector.

Novavax, Inc. Is a biotechnology company, which engages in the discovery, development, and commercialization of recombinant vaccines. The company was founded in 1987 and is headquartered in Gaithersburg, MD.

Novavax, Inc.

Novavax Inc

Novavax is actively trending as investors voice deep frustration with management's perceived inaction to secure partnerships, especially for its combination flu/COVID vaccine, a sentiment exacerbated by a competitor's recent acquisition. The community debates whether leadership's prolonged silence signals advanced buyout discussions or a strategic misstep, particularly as potential regulatory scrutiny on mRNA vaccines could highlight Novavax's protein-based platform as a differentiated alternative.

NIKE, Inc. engages in the design, development, marketing, and sale of athletic footwear, apparel, accessories, equipment, and services. It operates through the following segments: North America, Europe, Middle East, and Africa (EMEA), Greater China, Asia Pacific and Latin America (APLA), Global Brand Divisions, Converse, and Corporate. The North America, EMEA, Greater China, and APLA segments refer to the design, development, marketing, and selling of athletic footwear, apparel, and equipment. The Global Brand Divisions segment represents its NIKE Brand licensing businesses. The Converse segment designs, markets, licenses, and sells casual sneakers, apparel, and accessories. The Corporate segment is composed of unallocated general and administrative expenses. The company was founded by William Jay Bowerman and Philip Hampson Knight on January 25, 1964 and is headquartered in Beaverton, OR.

Nike, Inc. - Ordinary Shares - Class B

Nike Inc

Nike is trending as Apple CEO Tim Cook's recent stock purchase sparks significant community discussion, viewed by many as a strong vote of confidence in the company. While some dismiss the insider buy as insignificant, others believe it signals a potential turnaround for the sportswear giant, which has faced headwinds from China sales and tariff concerns.

Agios Pharmaceuticals, Inc. is a biopharmaceutical company, which engages in a research engine, multiple novels, and investigational therapies in preclinical development. It focuses on cellular metabolism and classical hematology. The company was founded by Lewis Clayton Cantley, Tak W. Mak, Craig B. Thompson and Shin-Shan Michael Su on August 7, 2007 and is headquartered in Cambridge, MA.

Agios Pharmaceuticals Inc

Agios Pharmaceuticals is trending following the FDA's expanded approval of AQVESME (mitapivat) for adults with alpha- or beta-thalassemia, establishing it as the first and only oral treatment for this condition. The community is actively discussing the commercial implications and the drug's high cost, while also reflecting on broader concerns about management's communication style and historical execution.

Zeta Global Holdings Corp. operates as a marketing technology software company, which engages in the provision of enterprises with consumer intelligence and marketing automation software. It enables its customers to target, connect and engage consumers through software that delivers marketing across all addressable channels, including email, social media, web chat, connected TV and video among others. The company was founded by David A. Steinberg and John Sculley on May 9, 2012 and is headquartered in New York, NY.

Zeta Global Holdings Corp - Ordinary Shares - Class A

Zeta Global Holdings Corp

Zeta Global is a focal point of market discussion following its Marigold acquisition and upcoming CES 2026 showcase, where its AI-powered Athena platform is expected to lead future marketing innovations. Despite analysts raising price targets and impressive growth metrics, the community expresses strong sentiment that the stock remains significantly undervalued and poised for a major re-rating, with many anticipating an explosive move driven by further AI developments.

UiPath, Inc. engages in the development and provision of a software platform to automate business processes. The firm serves the public, healthcare, telecommunication, finance, and banking industries. It also offers accounts payable automation, claims processing automation, contact center automation, and finance and accounting automation. The company was founded by Daniel Dines and Marius Tirca in 2005 and is headquartered in New York, NY.

UiPath Inc - Ordinary Shares - Class A

UiPath Inc

UiPath is experiencing significant buzz following its announced inclusion in the S&P MidCap 400 index, a move the community views as a major catalyst for increased institutional buying and enhanced market visibility. Investors are actively discussing its potential as a leader in Agentic AI automation, drawing comparisons to other high-growth tech plays, while some caution about near-term profit-taking.

Regencell Bioscience Holdings Ltd. is a early-stage bioscience company that focuses on research, development and commercialization of Traditional Chinese Medicine for the treatment of neurocognitive disorders and degeneration, specifically Attention Deficit Hyperactivity Disorder and Autism Spectrum Disorder. The company was founded by Yat-Gai Au on October 30, 2014 and is headquartered in Hong Kong.

Regencell Bioscience Holdings Ltd

Regencell Bioscience is trending amidst reports of significant insider buying from its CEO, fueling discussions around its extremely low float and potential for a short squeeze. Despite concerns regarding fundamental valuation and a past DOJ investigation into its volatility, the community is actively debating if its current momentum could replicate prior parabolic surges seen in similar speculative microcaps.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

The Zacks Analyst Blog Highlights iShares Silver Trust, United States Copper ETF and Invesco DB US Dollar Index Bullish Fund

Surging industrial demand, supply squeezes and a softer dollar outlook are positioning SLV, CPER and UUP at the center of 2026's metals-driven market narrative.

Will 2026 Be a Year of Silver & Copper ETFs?

SLV and CPER surge into 2026 as silver's supply squeeze and copper's structural demand ignite momentum. A dovish Fed and weaker dollar fuel the rally.

<ul class="summary-bullets"><li>&nbsp;Goldman does not expect supply shortages until 2029.</li><li>The firm expects copper prices to remain range-bound between $10,000 and $11,000 per ton.</li><li>The metal hit a record high of $11,540 per ton on the London Metal Exchange on Wednesday.</li></ul>&nbsp;Copper’s blistering rally drew fresh scepticism from Wall Street, with Goldman Sachs reportedly warning that the metal’s recent breakout is unlikely to last.On Wednesday, copper touched a record high of $11,540 per ton on the London Metal Exchange.<figure class="image"><img style="aspect-ratio:1303/882;" src="https://news.stocktwits-cdn.com/Copper_png_a14f2359ef.webp" alt="Copper.png" width="1303" height="882"><figcaption>Copper CFD | Source: TradingView</figcaption></figure>According to a Bloomberg report, Goldman Sachs said the latest surge has been driven more by expectations of future tightness than by current supply-demand fundamentals. “We do not expect the current breakout above $11,000 to be sustained,” analysts wrote.<h2 class="st-heading-2">What Drove The Prices?</h2>Prices have been propelled higher by concerns over a global supply squeeze, especially as traders rush metal into the U.S. ahead of potential tariffs. Trading giant Mercuria Energy Group recently warned of supply shortages emerging early next year. Still, Goldman believes global inventories may not fall to critically low levels. The firm expects demand to drop about half a million tons short of supply this year, and no shortages until 2029.“While our much smaller 2026 surplus of 160,000 tons moves the market closer to balanced, it means that we do not expect the global copper market to enter a shortage any time soon,” Goldman said, expecting prices to remain range-bound between $10,000 and $11,000 a ton.China’s near-term weakness is another factor tempering Goldman's outlook. The firm projects an 8% year-on-year drop in Chinese consumption in the fourth quarter, followed by a modest 2.8% rebound next year.<h2 class="st-heading-2">Why The Rally Could Continue</h2>Not everyone shares the cautious tone. JPMorgan expects the rally to extend, forecasting copper to reach $12,500 per ton by the second quarter of 2026. The firm highlighted rapid growth in data-center construction, which could add roughly 475,000 tons of copper demand in 2026, up about 110,000 tons from this year, as computing and AI-related infrastructure expands.The copper market has already gained more than 30% this year, with U.S. futures soaring even higher as investors bet the Trump administration will eventually impose broader tariffs on primary copper forms.Although July’s market panic over a rumored 50% tariff did not materialize, the administration left open the possibility of revisiting the decision in 2027, prompting traders to accelerate shipments to U.S. ports.According to Mercuria, these dynamics could spark an acute global supply squeeze by early next year, potentially pushing copper prices even deeper into record territory.Read also: <a href="https://stocktwits.com/news-articles/markets/equity/usar-stock-gains-16-as-newly-acquired-unit-strikes-rare-earth-deal-with-arnold-magnetic-technologies/cLIiTD4REjP">USAR Stock Gains 16% As Newly Acquired Unit Strikes Rare Earth Deal With Arnold Magnetic Technologies</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Goldman Sachs Warns Copper’s Record Run May Fizzle: Report

The latest surge has been driven more by expectations of future tightness than by current supply-demand fundamentals, Goldman Sachs said.

Equity

Copper ETF Appeal Grows Following Price Outlook Upgrade

From tightening supply to rate-cut tailwinds and a falling dollar, everything is lining up in copper's favor. Here's why ETFs tied to the red metal may benefit.

President Donald Trump on Wednesday imposed a 50% tariff on imports of semi-finished copper products into the United States, with the new levy coming into effect from August 1.In an announcement, the White House said the universal 50% tariffs apply to imports of semi-finished copper products, such as copper pipes, wires, rods, sheets, and tubes.Prices of the metal fell nearly 18% before recovering slightly to trade around $5.1 per pound at the time of writing.The&nbsp;<a href="https://stocktwits.com/symbol/CPER">United States Copper Index Fund</a> (CPER), which tracks the SummerHaven Copper Index, fell nearly 18%.However, in what would come as relief for the U.S. automobile industry, the White House said the copper tariffs will not stack on top of levies for imports of automobiles.If a product is also subject to auto tariffs, the copper duty will not be separately applicable, and instead, the import tax on vehicles will apply.The copper levies are applicable under Section 232 of the Trade Expansion Act.The Trump administration also invoked the Defense Production Act to require 25% of high-quality copper scrap and forms of raw copper produced in the U.S. to be sold within the country.U.S. equities traded mixed as investors reacted to the Federal Reserve keeping rates unchanged and President Trump announcing tariffs on Brazil and copper levies.At the time of writing, the&nbsp;<a href="https://stocktwits.com/symbol/SPY">SPDR S&amp;P 500 ETF</a> (SPY), which tracks the S&amp;P 500 index, was down 0.09%, while the&nbsp;<a href="https://stocktwits.com/symbol/QQQ">Invesco QQQ Trust</a> (QQQ) gained 0.16%. Retail sentiment around the S&amp;P 500 ETF on Stocktwits was in the ‘extremely bullish’ territory.For updates and corrections, email newsroom[at]stocktwits[dot]com.Also See:&nbsp;<a href="https://stocktwits.com/news-articles/markets/equity/palo-alto-networks-acquires-cyberark-25b-deal/choXcVkR5zy">Fed Keeps Rates Unchanged, Highlights Moderating Economic Activity In First Half</a>

U.S. President Donald Trump speaks to reporters on the South Lawn before boarding Marine One and departing the White House on July 01, 2025 in Washington, DC. 

Trump Slaps 50% Tariffs On Copper Imports

The White House announced that the universal 50% tariffs apply to imports of semi-finished copper products, such as copper pipes, wires, rods, sheets, and tubes.

Copper Skyrockets to New Highs: ETFs to Ride the Tariff Talks

CPER surges with copper hitting a record high in response to Trump's 50% tariff threat, with miners' ETFs like COPJ, COPP and COPA following suit.

Copper Hits a Three-Month High: ETFs in Focus 

Copper hit a three-month high near $10,000/ton as tight supply, strong demand, and trade optimism fuel gains. Tap CPER and COPX.

Did Copper’s Correction Destroy the Bull Market?

COMEX copper futures reached a new record high in March 2025, while the LME three-month copper forwards did not achieve the same feat. COMEX copper futures plunged in early April but held a critical technical support level and recovered.

Will Copper Make New Highs in 2025?

Copper prices reached new record highs in 2024. While the red metal declined from the peak, the price remains above $4 per pound as it consolidates its gains and decides if 2025 will bring another record high.

CPER
United States Commodity Funds LLC - United States Copper Index Fund

Feed

News

Sentiment

Fundamentals

Info

Latest CPER News

CPERUnited States Commodity Funds LLC - United States Copper Index Fund